Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Oliver & Co who wrote (2976)	11/24/1997 10:12:00 PM
From: JOHN W.	Read Replies (4) \| Respond to of 6136

There was a article today that suggested the fundamentals of a company may be changing because of competing products that are being rapidly developed. This statement is FALSE. The "interview" was anything but, and the source has had a crusade against this company. There is only one competing product ( PIs) that could be approved within the next 4 yrs. (VX-478-late98/99). Remember, 70% (key fact on the next competitor). There are other PIs that are being developed, but the term "rapidly" does not apply. The reference to this company was false, deliberately misleading, and highly suspicious. Disagree? Then please note the "competing" products (i.e. Protease Inhibitors) and their expected timeline to reach approval and the mkt. Facts simply don't support this vague and suspicious claim. These are the same people that note the lifespan of PIs and the potential size of this mkt. Then why so many competing products are being rapidly being developed. Their own claims, contradict. It is hard to keep lies straight. Hedge fund manipulators 1/individual investors 0.